SILVER SPRING, MD — Unanimously disappointed with the end point used to determine clinical benefit, advisors to the US Food and Drug Administration (FDA) agreed the Sentinel Cerebral Protection System ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...

Once reserved for very high-risk patients, the use of transcatheter aortic valve replacement in low-risk cases has increased ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

WASHINGTON, DC—An exploratory analysis of the PROTECTED TAVR trial suggests that use of the Sentinel cerebral embolic protection system (Boston Scientific) during TAVI had a greater impact in patients ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were ...

Indian-made Myval and Myval Octacor were put to the test against Sapien 3 in the noninferiority trial COMPARE TAVI-1. Noninferiority was demonstrated when counting deaths, strokes, moderate or severe ...

Concerns of hemolysis continued to swirl around the Sapien 3 Ultra Resilia, with yet another report indicating such harm after transcatheter aortic valve replacement (TAVR). In a single-center ...